SLC5A2 and diabetes mellitus: The development of SGLT2 inhibitors has not only generated a new treatments option for diabetes mellitus, but also a strategy to prevent cardiovascular and renal complications, thus leading to an extension of the therapeutic indication for some molecules of this drug class.